MRC1 and cancer: Based on these findings, we anticipate that the rHDL-DPM NPs are likely to improve TAM targeting and treatment outcome when combined with immunotherapy or PTX in vivo B16-F10 mouse models or in vivo models of cancers where the pro-tumoral M2-TAMs exhibit high SR-B1 and CD206 expression.